In terms of regulation 30 of the SEBI (Listing Obligations and Disclosure Requirement) Regulations, 2015, please find enclosed herewith a copy of Press Release for the Unaudited Financial results for the half year ended September 30, 2026.

October 29, 2026 BSE Limited Stock ID: TLL 14th Floor, P. J. Towers, Scrip Code: 543616 Dalal Street, Fort, ISIN: INE0MKA01014 Mumbai – 400001. Dear Sir/Madam, Sub: PRESS RELEASE FOR UNAUDITED FINANCIAL RESULTS FOR HALF YEAR ENDED SEPTEMBER 30, 2026 In terms of regulation 30 of the SEBI (Listing Obligations and Disclosure Requirement) Regulations, 2015, please find enclosed herewith a copy of Press Release for the Unaudited Financial results for the half year ended September 30, 2026. Kindly take the above information on record. Thanking you. YOURS FAITHFULLY, FOR TRIDENT LIFELINE LIMITED NIKITA SHARMA COMPANY SECRETARY AND COMPLIANCE OFFICER M NO: A60595 Registered Office: 2004, 2nd Floor, North Extension, Falsawadi, Ring Road, Surat-395003, Gujarat, INDIA. Tel : +91 261 2451274, 2451284 Email : info@tridentlifeline.com Web : www.tridentlifeline.com Factory Address: Plot No. 4240, Road No. 42, Sachin GIDC, Surat, Gujarat - 394230, India. PRESS & MEDIA RELEASE Q2 FY27 COMMENTARY HARDIK DESAI CHAIRMAN & EXECUTIVE DIRECTOR Dear Shareholders, Our vision has always extended beyond strengthening our core pharmaceutical formulations business. We believe that developing complementary businesses will create additional avenues for growth and enable us to build a more diversified healthcare platform with the potential to create long-term value. Guided by this vision, over the past decade we have consistently invested in manufacturing capabilities, regulatory approvals, infrastructure and new business verticals. These investments have laid the foundation for our current growth trajectory, and as our businesses scale and operational capabilities strengthen, we are beginning to realize the potential of the platform we have built. As we enter the next phase, our priority is to translate these capabilities into sustained business growth. This will require continued focus on execution, expanding our market presence, strengthening our product portfolio and improving operational efficiencies. As our newer business verticals progress beyond their initial development and incubation stages, we expect their contribution to our consolidated performance to increase meaningfully over time. Looking ahead, our aspiration remains to triple our consolidated business over the next three years. Achieving this ambition will depend on our ability to scale our business verticals successfully, execute our plans with discipline and allocate capital prudently. We remain committed to pursuing sustainable growth while creating enduring value for our shareholders over the long term. PRESS & MEDIA RELEASE Q2 FY27 COMMENTARY ASHISH BAFNA EXECUTIVE DIRECTOR & CHIEF FINANCIAL OFFICER Dear Shareholders, Q2 FY27 has been encouraging for Trident Lifeline Limited, reflecting strong business growth, improved profitability, and continued progress towards our long-term strategic objectives. Our consolidated revenue from operations grew by approximately 50% to ₹47.1 crore, compared with ₹31.3 crore in the corresponding period last year. Consolidated profit after tax increased by approximately 30% to ₹6.6 crore, from ₹5.1 crore. On a standalone basis, revenue grew by approximately 19.3% to ₹32.7 crore, while profit after tax increased by approximately 33.1% to ₹6.6 crore, compared with ₹4.9 crore in the previous corresponding period. These results reflect the growing scale of our business and our continued focus on profitable growth. Our performance is supported by progress in product registrations, expansion into new markets, additions to our product portfolio, contributions from subsidiaries, and improving utilisation of our existing manufacturing capacities. We are also progressing with the commissioning of our parenterals facility, which is expected to be commissioned after Diwali, subject to operational readiness. This will strengthen our manufacturing capabilities and support our future growth plans. The proposed preferential issue will further strengthen our financial resources. The proceeds will support the Company’s strategic priorities and provide a foundation for the next phase of expansion. During the H2 FY27, our focus will remain on improving capacity utilisation, accelerating execution, expanding our product and market presence, strengthening subsidiary performance, and maintaining financial discipline. Looking ahead, we remain committed to our ambition of tripling our consolidated business over the next three years. With our expanding platform, stronger execution capabilities, and disciplined approach to growth, we believe Trident Lifeline is well positioned to create sustainable long-term value for its shareholders. Thank you for your continued trust and support. PRESS & MEDIA RELEASE INCOME STATEMENT ₹ crores unless otherwise mentioned Q2 Q2 YoY Q1 QoQ Particulars Q4 FY26 Q3 FY26 FY26 FY27 FY26 change FY27 change Revenue 47.1 31.3 50% 33.7 40% 50.0 25.7 129.0 EBITDA 11.3 6.9 65% 8.5 33% 11.0 5.1 28.1 EBITDA margin (%) 24.1% 21.9% 217 bps 25.3% (120 bps) 22.0% 19.8% 21.8% PAT 6.6 5.1 30% 5.1 30% 6.8 4.6 19.3 PAT margin (%) 14.0% 16.2% (224 bps) 15.0% (102 bps) 13.6% 18.1% 15.0% About Trident Lifeline Limited: Trident Lifeline Limited (“Trident Lifeline” or the “Company”) is a pharmaceutical and healthcare company with expertise in manufacturing finished dose pharmaceutical products, with a growing presence across global markets. The Company offers a diversified portfolio spanning pharmaceuticals, nutraceuticals, herbal products, injectables, personal care and medical devices, catering to a broad range of healthcare needs. Its operations are supported by a hybrid manufacturing model combining strategic manufacturing partnerships with integrated capabilities, enabling scalability, product quality and supply reliability. Trident Lifeline focuses on delivering quality-led healthcare solutions across domestic and international markets, supported by regulatory-compliant manufacturing capabilities, an expanding product portfolio and an established global distribution network. Contact us: Company Investor relations consultant Trident Lifeline Limited NeoAtlas Capital Advisory LLP Nikita Sharma Preet Choradiya Company Secretary +91 7383201103 | research@atlascapital.in compliance@tridentlifeline.com Rutul Shah +91 8200247366 | rutul.shah@atlascapital.in Meeting Request Link Safe harbor - Certain statements in this document that are not historical facts are forward looking statements. Such forward looking statements are subject to certain risks and uncertainties like government actions, local, political or economic developments, technological risks, and many other factors that could cause actual results to differ materially from those contemplated by the relevant forward-looking statements. Trident Lifeline Limited will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward- looking statements to reflect subsequent events or circumstances.